Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

Bristol-Myers Squibb (BMS) building

BMS trades blows with investor on Celgene deal merits

Activist investors claim Celgene’s pipeline is “extremely risky”

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

- PMLiVE

Depression drug failure adds to Allergan’s woes

Axe hangs over remaining monotherapy and suicidality trials

Bedrock strengthens Scientific Services team

The appointment of a Head of Scientific Services will reinforce the company’s core medical communications offering

Bedrock Healthcare Communications

- PMLiVE

J&J’s Spravato breaks depression drought at FDA

The esketamine nasal spray is the first new-mechanism antidepressant to be licensed in decades

- PMLiVE

FDA chief Scott Gottlieb to step down

Won admiration of industry and public health experts

- PMLiVE

UK biotech bags €1.5m grant for new antibiotic class

Procarta is one of four start-ups that received the grant

- PMLiVE

Riva leaves Gilead to head Glenmark’s innovation spin-off

Company has own bispecific antibody platform

- PMLiVE

How to fix a problem like Orkambi? Solutions suggested ahead of showdown

Approaches used in France and Germany could help break deadlock

- PMLiVE

Precision BioSciences to raise $100m for off the shelf CAR-Ts

Joins next wave of cell therapy competitors

- PMLiVE

CHMP backs Lynparza in breast cancer, Dupixent in asthma

Akcea's FDA-rejected Waylivra also recommended

- PMLiVE

Positive data unlocks more EIB funding for Nanobiotix

The cash is earmarked for its head and neck cancer drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links